For the second part of this interview, please see: Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Mikhail Kosiborod, MD, is Professor of Medicine, University of Missouri Kansas City, Vice President, Research, Saint Luke’s Health System, Executive Director, Cardiometabolic Center Alliance, Director, Cardiometabolic Research and Co-director, Haverty Cardiometabolic Center of Excellence, Saint Luke’s Mid America Heart Institute, Kansas City, MO.
Neil Skolnik, MD, is Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.